


# Ambulatory Care Revolution – Value Based Purchasing Across the Continuum


Jonathon Truwit, MD, MBA Enterprise Chief Medical Officer and Sr. Admin Dean Froedtert & Medical College of Wisconsin Milwaukee, WI


### **Objectives**


- Discuss the revolution occurring with acquisitions and new businesses established to meet payer demands for performance and shared risk in health care costs.
- Discuss the perspectives of the C-suite on ambulatory care needs in infrastructure, management of work force, and revenue management to ensure sustainability and success.
- Describe implications of technology and personalized medicine for health systems.
- Identify areas of opportunity for pharmacy leaders preparing for success in the changing health care environment.


































# ❖ Multispecialty group practices provide higher quality of care on selected preventive and process measures involving recommended screening tests and diabetes and asthma management...than smaller, looser forms of practice" ■ Stephen M. Shortell 2008 ❖ Standardized physician spending was \$239 (8.0 percent) lower; standardized hospital spending was \$235 (9.7 percent) lower; and total standardized Medicare payments were \$540 (7.1 percent) lower for such patients." ■ Elliott Fisher 2010





# Why push for PCPs? ❖Increase patient population footprint ❖Diversification of disease burden ❖Create footprint for multispecialty systems ❖Limited resource • Strike now or be left behind



### **Leverage the Team**

- PCPs not enough in population health
  - Advanced Practice Practitioners
  - Nurses
  - Pharmacy
  - · Case managers
  - Medical Assistants
- Population per unit team
  - Target 3k-5k patients per team general medical patients
  - Target 300-500 patients per team high utilizer clinic, patients with multiple chronic diseases





### Mergers, Acquisitions Territorial Control



Imperialistic Approach

ProsC

- Control, Integration, and Alignment
- Cons
  - Capital expensive
  - · Resentment and Mutiny
  - Conflict with academic mission



# Collaborative Network of Independent Organizations with Common Shared Risk




- Pros
  - · Less capital resources
  - Rationalization of care
- Cons
  - Competition of collaboration over clinical and finances
    - Coopetition
  - Governance





### What will the Alliance lead to?

- ❖ Rationalization of Care
  - Utilization
  - Location
- Care delivery models that meet the patient where they are
  - Traditional and digital
  - · Physicians and non-physicians




















































IT Support Breakout


What resources from IT are needed to enable teams to provide value?














Digital Health Breakout

What digital opportunities are available to promote value?


Report out from Breakouts
















### **Froedtert & Medical College of Wisconsin**

- F&MCW is developing and implementing a new paradigm to healthcare
  - · Needs to be patient/consumer centered
  - Needs to reduce costs and utilization and improve quality and service
  - Needs to be work for different payment models
  - Needs to leverage our academic community partnership, our growth and our multi-system ACO
- ❖ VIDEO

University Hospital Consortium model





### **Pharmacy Breakout**

Given your findings during this session what role can pharmacy play to promote value?

ashp







### **PCCPS Population Health Initiatives**

### Patient Safety

- · Eliminated "as needed" on long-acting opioid scripts
- Reduced NSAIAs in Chronic Kidney Disease patients
- Decreased use of diazepam for patients >65 years
- Reviewed long-acting  $\beta$ -agonists w/o inhaled corticosteroids in patients with asthma

Heilmann RM et al. Ann Pharmacother. 2013; 47:124-31.



### **PCCPS Population Health Initiatives**

### Quality of Care

- Reviewed/developed plans for HTN prior to RN visits
- Recommended change from raloxifene/etidronate to bisphosphonate when appropriate
- Reviewed meds for increased fall risk or urinary incontinence in patients ≥65 years of age
- Reviewed plans for females <u>>67</u> years of age with fracture to determine need fro BMD or osteoporosis medication

Hellmann RM et al. Ann Pharmacother. 2013; 47:124-3:



## 

### **PCCPS Population Health Initiatives**

### Affordability

- Assessed patients using multiple inhalations of inhaled corticosteroids for conversion to a more potent agent
- Evaluated patients for generics or lower cost substitution
  - Migraine triptan, UC mesalamine, HSV famciclovir to acyclovir, non-CHF patients: metoprolol succinate XL to immediate-release βblocker

Heilmann RM et al. Ann Pharmacother. 2013; 47:124-31.



### Team Based Care: PCMH and MTM

- ❖ CHF 12 RCTs (n = 2,060)
  - CHF hospitalizations: OR 0.69 (95% CI: 0.51 to 0.94)
- ❖ Hyperlipidemia 7 RCTs (n = 924)
  - LDL reduced by **-13.4%** (95% CI: -23.0% to -3.8%)
- **❖** Hypertension 19 RCTs (*n* = 10,479)
  - SBP reduced by **-8.1 mm Hg** (95% CI: -10.2 to -5.9)
- ❖ Diabetes 14 RCTs (n = 2,073)
  - HgA1C reduced by -0.76% (95% CI: -1.06 to -0.47)
- CKD 8 RCTs (n = 688)
  - ESRD/Death in DM Nephro: 14.8 v 28.2/100 patient-years

Odum et al. Cardiorenal Med. 2012; 2:243-50





### **Advocate Physician Partners**

- ❖ Governance led by physicians
- Oncology Clinical Pharmacist
  - Develop and maintain specialty/oncology related protocols
- ❖ Educate and collaborate with physicians
  - · Develop CME program that was mandatory
- Provide value added services

Patterson CJ. J Manag Care Pharm. 2013; 19:42-8







### **Value Added Services Provided in FY12**

Services Provided	Quantity
Claims Denial and approval consultations	7
Drug information questions answered	23
Drug summaries sent to providers	6
Educational presentations	11
Newsletter publications	12
In-office physicians visits	19
Pharmacy and Therapeutics presentations provided	31

Patterson CJ. J Manag Care Pharm. 2013; 19:42-8.

ashp

### **Unplanned Readmissions in Older Patients?**

- ❖When led by hospital pharmacists
  - Risk Ratio 0.97 (0.88-1.07) NS
- ❖When led by community pharmacists
  - Risk Ratio 1.07 (0.96-1.20) NS
- **❖**However
  - 3 RCTs for older patients with CHF show a 25% reduction in unplanned readmissions



## **Objectives**

- Discuss the revolution occurring with acquisitions and new businesses established to meet payer demands for performance and shared risk in health care costs.
- Discuss the perspectives of the C-suite on ambulatory care needs in infrastructure, management of work force, and revenue management to ensure sustainability and success.
- Describe implications of technology and personalized medicine for health systems.
- Identify areas of opportunity for pharmacy leaders preparing for success in the changing health care environment.

